Samantha Vermaak

Samantha Vermaak

Co-Investigator & Executive Manager, VALIDATE Vaccine R&D Network

University of Oxford, UK

Tel: +44 (0)1865 611428






Network Co-Investigator & Executive Manager, Management Team Member, Network Management Board Member



Sam is the Executive Manager of VALIDATE, based at University of Oxford. As a member of the Management Team and Network Management Board she helps plan VALIDATE's strategic direction and leads on operations, with responsibility for turning plans into actual VALIDATE activities, as well as being responsible for VALIDATE's financial management. She heads up the VALIDATE core staff team at University of Oxford.

Managing VALIDATE from its inception in 2017, and as TB Vaccine Programme Manager at Oxford's Jenner Institute for seven years prior to this, Sam has extensive experience in project/programme management, research grant financial management, managing clinical trials in the UK and overseas, working with industry partners, and managing international Consortia. Sam is also a trained coach and leads the VALIDATE Early Career Researcher Career Development Network (ECDN).


Related Websites: 




1. Michael Riste, Julia L. Marshall, Iman Satti, Stephanie A. Harris, Morven Wilkie,Raquel Lopez Ramon, Danny Wright, Rachel Wittenberg, Samantha Vermaak, Rebecca Powell Doherty, Alison Lawrie, Christopher P. Conlon, Catherine Cosgrove, Fergus Gleeson, Marc Lipman, Paul Moss, Felicity Perrin, Martin Dedicoat, Henry Bettinson and Helen McShane. 2021. Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults. Vaccines 2021,9, 396  PMID: 33923628  

2. Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, Wright D, Stockdale L, Hamidi A, O'Shea MK, Dwivedi K, Behrens HM, Davenne T, Morton J, Vermaak S, Lawrie A, Moss P, McShane H. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2020 38(4):779-789 PMID: 31735500

3. Manjaly Thomas ZR, Satti I, Marshall JL, Harris SA, Lopez Ramon R, Hamidi A, Minhinnick A, Riste M, Stockdale L, Lawrie AM, Vermaak S, Wilkie M, Bettinson H, McShane H. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Med. 2019 Apr 30;16(4):e1002790. PMID: 31039172 

4. Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye, PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H. 2018. VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy F1000Research 2018, 7:485 PMID: 29904595. 

5. Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan S, Stockdale L, Manjaly Thomas ZR, Lopez-Ramon R, Poulton I, Lawrie A,Vermaak S, Le Vert A, Del Campo J, Hill F, Moss P, McShane H. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. Vaccine. 2016 Mar 8;34(11):1412-21 Epub 2016 Feb 5. PMID: 26854906

6. Sheehan S, Harris SA, Satti I, Hokey DA, Dheenadhayalan V, Stockdale L, Manjaly Thomas ZR, Minhinnick A, Wilkie M, Vermaak S, Meyer J, O'Shea MK, Pau MG, Versteege I, Douoguih M, Hendriks J, Sadoff J, Landry B, Moss P, McShane H. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS One. 2015 Nov 3;10(11):e0141687. PMID: 26529238 

7. Minhinnick A, Harris S, Wilkie M, Peter J, Stockdale L, Manjaly-Thomas ZR, Vermaak S, Satti I, Moss P, McShane H. Optimisation of a human BCG challenge model: a tool to evaluate anti-mycobacterial immunity. J Infect Dis. 2016 Mar 1;213(5):824-30 PMID: 26450421 

8. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015 Mar;3(3):190-200. PMID: 25726088

9. Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. PLoS One. 2014 Feb 3;9(2):e87340. PMID: 24498312 

10. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8. PMID: 23391465